Cargando…

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

INTRODUCTION: Pegargiminase (ADI-PEG 20; ADI) degrades arginine and potentiates pemetrexed (Pem) cytotoxicity in argininosuccinate synthetase 1 (ASS1)–deficient malignant pleural mesothelioma (MPM). We conducted a phase 1 dose-expansion study at the recommended phase 2 dose of ADI-PEG 20 with Pem an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szlosarek, Peter W., Phillips, Melissa M., Pavlyk, Iuliia, Steele, Jeremy, Shamash, Jonathan, Spicer, James, Kumar, Sanjeev, Pacey, Simon, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John, Moir, Graeme, Lau, Kelvin, Ellis, Stephen, Sheaff, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474273/ https://www.ncbi.nlm.nih.gov/pubmed/34589965 http://dx.doi.org/10.1016/j.jtocrr.2020.100093

Ejemplares similares

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
por: Beddowes, Emma, et al.
Publicado: (2017)

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

Role of 3'-Deoxy-3'-[(18)F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase
por: Szyszko, Teresa A., et al.
Publicado: (2022)

A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma
por: Chan, Pui Ying, et al.
Publicado: (2022)

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer
por: Szlosarek, Peter W., et al.
Publicado: (2021)

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
por: Syed, N, et al.
Publicado: (2013)

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
por: Delage, B, et al.
Publicado: (2012)

Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas
por: Cheon, Dong‐Joo, et al.
Publicado: (2014)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
por: Kelly, M P, et al.
Publicado: (2012)

Epithelial argininosuccinate synthetase is dispensable for intestinal regeneration and tumorigenesis
por: van der Meer, Jonathan H. M., et al.
Publicado: (2021)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

A transgenic approach to study argininosuccinate synthetase gene expression
por: Shiue, Shih-Chang, et al.
Publicado: (2014)

Bench-to-Bedside Studies of Arginine Deprivation in Cancer
por: Field, George C., et al.
Publicado: (2023)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Cytosolic Delivery of Argininosuccinate Synthetase Using a Cell-Permeant Miniature Protein
por: Knox, Susan L., et al.
Publicado: (2021)

Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1
por: Locke, Matthew, et al.
Publicado: (2016)

Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer
por: SHAN, YAN-SHEN, et al.
Publicado: (2015)

Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance
por: Kim, Youngji, et al.
Publicado: (2016)

Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines
por: Shan, Yan-Shen, et al.
Publicado: (2015)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells
por: Zheng, Liang, et al.
Publicado: (2013)

Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model
por: Shiue, Shih-Chang, et al.
Publicado: (2015)

Citrullinemia type I in Chinese children: Identification of two novel argininosuccinate synthetase gene mutations
por: Xiong, Mei, et al.
Publicado: (2022)

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma
por: Liu, Qingqing, et al.
Publicado: (2017)

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
por: Kim, Stephanie S., et al.
Publicado: (2020)

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
por: Thongkum, Angkana, et al.
Publicado: (2017)

High-throughput enrichment of temperature-sensitive argininosuccinate synthetase for two-stage citrulline production in E. coli
por: Schramm, Thorben, et al.
Publicado: (2020)

RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells
por: Wu, Fe-Lin Lin, et al.
Publicado: (2011)

Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines
por: Roeksomtawin, Somphon, et al.
Publicado: (2018)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
por: Qin, Yiyang, et al.
Publicado: (2017)

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
por: Bearz, Alessandra, et al.
Publicado: (2012)

Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma
por: Biersack, Bernhard
Publicado: (2018)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma
por: Youk, Jeonghwan, et al.
Publicado: (2017)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
por: Liu, Jiangbo, et al.
Publicado: (2014)

Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy
por: McAlpine, Jennifer A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j6ei9eei01gib5kh54ku791n17